Novartis Korea breaks 200 billion won in 2006 salses
Published: 2007-01-16 07:00:00
Updated: 2007-01-16 07:00:00
In just three years, Novartis Korea pushed up its annual sales by a whopping a 200 billion won level backed by robust business growth of its flagship products, including Diovan, a highly selective angiotensin II receptor blocker (ARB).
Last year, Novartis Korea chalked up 182.3 billion won in ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
